Company Of The Day: Pfizer

+3.09%
Upside
27.75
Market
28.61
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer’s (NYSE:PFE) Covid-19 vaccine could be available to children from ages five to eleven as soon as the end of October, per a report from Reuters.

Why?

Relevant Articles
  1. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  2. Should You Pick Pfizer Stock At $30?
  3. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
  4. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  5. Is Pfizer Stock Undervalued At $40?
  6. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

Pfizer and its partner BioNTech could have sufficient data from clinical trials for the age group to file for emergency use authorization (EUA) by the end of this month.

So What?

Pfizer stock remains up by about 21% year-to-date, driven by soaring demand for the Covid-19 vaccine. A potential approval for children should expand the addressable market for the shot further.

See Our Complete Analysis For Pfizer